帕利哌酮缓释片治疗老年精神分裂症患者的研究进展  

The research progress of the elderly schizophrenia using paliperidone extended-release tablets

作　　者：蔡清艳 张岚[1] 简薇[2] 

机构地区：[1]四川大学华西医院心理卫生中心,成都610041 [2]成都市第四人民医院,成都610036

出　　处：《中国新药杂志》2017年第9期1029-1033,共5页Chinese Journal of New Drugs

摘　　要：帕利哌酮缓释片是一种较新的非典型抗精神病药,主要通过拮抗D_2受体和5-HT_(2A)受体发挥抗精神病的治疗作用,同时还有较强的D3_受体阻断及5-HT_7受体阻断作用,从而改善患者的认知功能与睡眠问题。近年来,帕利哌酮缓释片在临床工作中逐渐得到了广泛应用,其在老年精神分裂症患者的治疗中有明显的优势,使用比例也越来越大。本文简要阐释了老年精神病患者选药的特殊性、帕利哌酮缓释片的药理特点及对血糖、血脂、泌乳素及体重的影响,也比较分析了帕利哌酮缓释片与其他抗精神病药物的疗效与安全性等;并在综合既往研究与最新研究证据及临床经验的基础上,综述了帕利哌酮缓释片在老年精神分裂症患者中的临床疗效与安全性。Paliperidone extended-release （ER） tablets is a relatively new atypical antipsychotic drug, which plays a role of antipsychotic therapy through antagonism of D2 receptor and 5-HT2A receptor, as well as strong blocking effect of D3 receptor and 5-HT7 receptor, so as to improve cognitive function and solve sleeping problems in patients. In recent years, paliperidone ER has been widely used in clinical practice, and it has obvious advantages in the treatment of schizophrenia in elderly patients. This paper briefly explained the specificity of drug selection in elderly patients with mental disorders, the pharmacological characteristics of paliperidone ER and its effects on blood glucose, blood lipid, prolactin and body weight, and compared the efficacy and safety of paliperidone ER with other antipsychotic drug. On the basis of previous research and the latest research evidence and clinical experience, the clinical efficacy and safety of paliperidone ER in elderly patients with schizophrenia were mainly reviewed.

关 键 词：老年精神分裂症 帕利哌酮缓释片 疗效 安全性 

分 类 号：R971.41[医药卫生—药品]